Century Therapeutics Q3 net loss $32.7M, appoints Brent Pfeiffenberger CEO

Century Therapeutics, Inc.

2023-Q3 EPS reported -$1.65 revenue$1,967,000

Brent Pfeiffenberger appointed CEO effective Dec 4, 2023; Greg Russotti becomes Chief Technology and Manufacturing Officer.
Cash and investments $284.3M as of Sep 30, 2023; cash runway into 2026.
Q3 2023 net loss $32.7M vs $30.7M in Q3 2022; R&D expenses down to $22.8M from $25.9M.
Expanded license with FUJIFILM Cellular Dynamics for iPSC-derived cell therapies in autoimmune/inflammatory diseases.
Initial Phase 1 ELiPSE-1 data for CNTY-101 in B-cell lymphomas to be presented at ASH Dec 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Century Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $0.1 million, net income $32.7 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $0.1 million
Net income: $32.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(BMS) collaboration of $118.5 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option, and license agreement with BMS was $0.1 million for the three months ended September 30, 2023 compared to $2.2 million for the same period in 2022. Revenue recognized under the collaboration agreement fluctuates based on the

View on SEC.gov

Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.